You are viewing: US Real World Evidence Solutions Market analysis

The US Real World Evidence Solutions Market was valued at $2880.6 Million in 2025 and projected to reach to $5624.2 Million by 2030, representing a compound annual growth rate of 14.3%. The US Real World Evidence Solutions Market is poised for sustained expansion as healthcare stakeholders increasingly recognize the value of real-world data in complementing traditional clinical evidence.

US Real World Evidence Solutions Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Real World Evidence Solutions Market Trends and Insights

  • This expansion reflects the US healthcare system's increasing reliance on real-world data to complement clinical trial evidence and inform treatment decisions.
  • The US market is driven by regulatory support, growing adoption among pharmaceutical and biotech companies, and the need for post-market surveillance and health outcomes research. In 2025, the US represents a mature yet rapidly evolving market where healthcare providers, payers, and life sciences organizations are integrating real-world evidence into clinical workflows and reimbursement strategies.
  • By 2030, the US market is expected to nearly double, supported by advances in data analytics, interoperability standards, and the FDA's continued emphasis on real-world performance data.
  • The US dominance in this space reflects its sophisticated healthcare infrastructure and substantial investment in digital health technologies. The 14.3% compound annual growth rate underscores the US market's acceleration as stakeholders recognize the value of real-world evidence in reducing development timelines, optimizing patient populations, and demonstrating clinical value beyond traditional endpoints..

Key Market Statistics

  • CAGR (2025-2030) 14.3% CAGR
  • Market Size, 2025 ~USD 2880.6 Million
  • Forecast, 2030 ~USD 5624.2 Million
  • Country US

US Real World Evidence Solutions Market Overview

Market Valuation Growth :

The US Real World Evidence Solutions Market is valued at $2,880.6 million in 2025 and is projected to reach $5,624.2 million by 2030, representing a robust 14.3% CAGR over the forecast period.

Regulatory Support Driving Adoption :

The FDA and other US regulatory bodies increasingly recognize real-world evidence as a complement to traditional clinical trials, accelerating adoption across pharmaceutical companies and healthcare providers seeking faster market approvals and post-market surveillance.

Pharmaceutical Industry Leadership :

US pharmaceutical companies are leading the adoption of RWE solutions to optimize drug development, reduce clinical trial costs, and demonstrate real-world effectiveness to payers and healthcare systems for improved reimbursement decisions.

Healthcare System Integration :

US healthcare providers are increasingly integrating real-world data from electronic health records, claims databases, and patient registries to support evidence-based clinical decision-making and improve patient outcomes across diverse populations.

US Real World Evidence Solutions Market Dynamics

  • Regulatory agencies continue to support RWE integration into drug approval processes, while pharmaceutical companies invest heavily in data analytics capabilities to reduce development timelines and costs.
  • Healthcare providers and payers are leveraging RWE to optimize treatment protocols and justify reimbursement decisions based on actual patient outcomes. Looking ahead, the US market will be shaped by advancing data interoperability standards, growing investment in AI-driven analytics platforms, and expanding real-world data sources including wearables and digital health tools.
  • The convergence of regulatory encouragement, technological innovation, and economic pressures to demonstrate value will continue driving market growth through 2030, positioning the US as a global leader in RWE adoption and implementation..

Related Ecosystem

Healthcare It

Top Technologies
  • Computed Tomography (CT)
  • Machine Learning
  • Magnetic Resonance Imaging (MRI)
  • Natural Language Processing (NLP)
  • Predictive Analytics
Top Companies
  • CERNER CORPORATION
  • PHILIPS HEALTHCARE
  • Oracle Corporation
  • GE HealthCare Technologies Inc.
  • Siemens healthineers

    Key Takeaways

    • The US Real World Evidence Solutions Market is valued at $2,880.6 million in 2025 and is forecast to reach $5,624.2 million by 2030, representing a 14.3% CAGR.
    • The US market benefits from strong regulatory tailwinds, with the FDA actively encouraging the use of real-world evidence in drug approvals and post-market surveillance.
    • By 2030, the US market will nearly double in size as pharmaceutical companies, healthcare systems, and payers increasingly integrate real-world data into clinical and commercial decision-making.
    • The US dominates the global real-world evidence landscape due to advanced healthcare infrastructure, robust data ecosystems, and significant investment in digital health innovation.

    Real World Evidence Solutions Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment INTEGRATED DATA SETS (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 14.8% from 2025 to 2030
    Largest Segment CLOUD-BASED (Deployment Mode)
    Market Size Base Year (Billions) ~USD 5.43 (2025)
    Revenue Forecast (Billions) ~USD 10.83 (2030)
    Segments Covered Component, Type, Application, Therapeutic Area, Revenue Model, Deployment Mode, End User, Healthcare Payer, Healthcare Provider

    US Real World Evidence Solutions Market Report Segmentation

    9 segment dimensions are covered across the global market.

    By Component

    • Data Sets
    • Services

    By Type

    • Cardiovascular Diseases
    • Claims Data Sets
    • Clinical Settings Data
    • Clinical Settings Data Sets
    • Clinics & Other Outpatient Settings
    • Disparate Data Sets
    • Hospitals
    • Immunology
    • Integrated Data Sets
    • Neurology
    • Oncology
    • Other Healthcare Providers
    • Other Types
    • Patient-Powered Data Sets
    • Pharmacy Data Sets
    • Private Payers
    • Public Payers
    • Rare Diseases
    • Registry-Based Data Sets

    By Application

    • Clinical & Regulatory Decision-Making
    • Clinical &Regulatory Decision-Making
    • Clinical And Regulatory Decision-Making
    • Drug Development & Approvals
    • Drug Development And Approvals
    • Market Access & Reimbursement/ Coverage Decision-Making
    • Market Access & Reimbursement/Coverage Decision Making
    • Market Access And Reimbursement/ Coverage Decision Making
    • Medical Device Development & Approvals
    • Medical Device Development And Approvals
    • Other Applications
    • Post Market Surveillance
    • Post-Market Surveillance

    By Therapeutic Area

    • Cardiovascular Diseases
    • Immunology
    • Neurology
    • Oncology
    • Other Therapeutic Areas
    • Rare Diseases

    By Revenue Model

    • License
    • Pay-Per-Usage (Value-Based Pricing)
    • Subscription

    By Deployment Mode

    • Cloud-Based
    • Hybrid
    • On-Premises

    By End User

    • Healthcare Payers
    • Healthcare Providers
    • Medtech Companies
    • Other End Users
    • Pharmaceutical & Biotechnology Companies

    By Healthcare Payer

    • Private Payers
    • Public Payers

    By Healthcare Provider

    • Clinics & Other Outpatient Settings
    • Hospitals
    • Other Healthcare Providers

    US: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    HEALTHCARE PAYERS440.4498.1564.1639.5725.8824.7938.31068.713.6
    HEALTHCARE PROVIDERS545622710.8813.1931.21067.71225.71408.614.7
    MEDTECH COMPANIES335.4384.3440.9506.4582.3670.3772.5891.415.1
    OTHER END USERS139.1156.8176.9199.8225.8255.4289.1327.513.1
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES762.3867.3987.91126.71286.31470.41682.71927.914.3
    TOTAL2222.12528.62880.63285.43751.44288.54908.35624.214.3

    Target Audience

    • Pharmaceutical Companies : US pharma firms need detailed market intelligence to optimize real-world evidence strategies for drug development, regulatory submissions, and post-market surveillance while understanding competitive positioning and payer requirements.
    • Healthcare Providers and Health Systems : US hospitals and healthcare networks require market insights to evaluate RWE solutions for clinical decision support, quality improvement initiatives, and demonstrating value to payers and patients in their specific geographic markets.
    • Payers and Insurance Companies : US health insurers and managed care organizations need market data to assess RWE tools for coverage decisions, health economics analysis, and population health management to optimize reimbursement strategies and patient outcomes.
    • RWE Technology Vendors : US-based and international RWE solution providers require comprehensive market analysis to identify growth opportunities, customer segments, competitive threats, and emerging technology trends to refine product development and sales strategies.
    • Healthcare Investors and Consultants : Investment firms and management consultants need US market-specific data to evaluate investment opportunities, assess portfolio company positioning, and provide strategic guidance on real-world evidence market dynamics and growth potential.

    Key Companies in the US Real World Evidence Solutions Market

    CompanyHQOwnershipStrongest segments
    IQVIAUnited StatesPublic CompanyTechnology & Analytics Solutions,Research & Development Solutions,Contract Sales & Medical Solutions,
    ICON PLCIrelandPublic CompanyFull-service clinical development (Phase I–IV, peri/post-approval),Functional service partnerships & contract staffing,Laboratory, bioanalytical, biomarker, and imaging services,
    SYNEOS HEALTHUnited StatesPrivate CompanyClinical Development Services,Commercialization & Launch Services,Consulting, Advisory & Data/Software,
    PAREXEL INTERNATIONAL (MA) CORPORATIONUnited StatesPrivate CompanyClinical trial management and monitoring,Biostatistics and data management,Regulatory affairs and pharmacovigilance,
    FLATIRON HEALTHUnited StatesSubsidiaryOncology EHR and practice management software,Life sciences real-world data subscriptions and licensing,Evidence-generation partnerships and analytics services,
    FORTREAUnited StatesPublic CompanyClinical Development (Phase I–IV and RWE),Clinical Pharmacology and Early Development,Consulting, Market Access, HEOR and RWE Services,
    ORACLEUnited StatesPublic CompanyCloud SaaS (Fusion ERP/EPM/SCM/HCM, NetSuite, CX),Cloud Infrastructure & Autonomous Database,On-Premise Licenses & License Support,
    ELEVANCE HEALTHUnited StatesPublic CompanyHealth Benefits (Commercial & Specialty),Health Benefits (Government: Medicare, Medicaid, FEP),CarelonRx (Pharmacy Services),
    TRINITYUnited StatesPublic CompanyRailcar Leasing and Services Group,Rail Products Group,
    MEDIDATAUnited StatesPrivate CompanyCore EDC and clinical data management,Decentralized trial and patient engagement solutions,Advanced analytics and data-driven services,

    IQVIA

    IQVIA is a large public company headquartered in the United States with approximately 93,000 employees. The company operates in the healthcare and life sciences industry.

    ICON PLC

    Icon PLC is a public company founded in 1989 and headquartered in Ireland. With 40,350 employees, the company provides clinical research and development services globally.

    SYNEOS HEALTH

    Syneos Health is a private company founded in 2010 and based in the United States. With 28,768 employees, the company offers clinical research, consulting, and commercial services to the life sciences industry.

    PAREXEL INTERNATIONAL (MA) CORPORATION

    Parexel International (MA) Corporation is a private company founded in 1982 and headquartered in the United States. With 18,900 employees, the company provides clinical research, consulting, and regulatory services to the pharmaceutical and biotech industries.

    FLATIRON HEALTH

    FlatIron Health is a subsidiary company founded in 2012 and based in the United States. The company specializes in oncology software and data solutions for healthcare providers.

    FORTREA

    Fortrea is a public company founded in 2023 and based in the United States. With 14,000 employees, the company operates in the clinical research and contract research organization sectors.

    ORACLE

    Oracle is a large public technology company founded in 1977 and headquartered in the United States. With 141,000 employees, the company develops database software, cloud computing solutions, and enterprise applications.

    ELEVANCE HEALTH

    Elevance Health is a public company founded in 2001 and based in the United States. With 96,615 employees, the company operates as a major health insurance and managed care provider.

    TRINITY

    Trinity is a public company founded in 1933 and headquartered in the United States. With 6,110 employees, the company operates in the healthcare services sector.

    MEDIDATA

    Medidata is a private company founded in 1999 and based in the United States. With 1,998 employees, the company provides cloud-based clinical trial software and data analytics solutions for the life sciences industry.

    Reasons to Buy this Report

    • Accurate US Market Sizing : Obtain precise valuation data specific to the US market with detailed historical analysis and forward-looking projections through 2030, enabling accurate budget allocation and investment planning for US-focused business strategies.
    • Regulatory Landscape Insights : Understand FDA and US regulatory agency positions on real-world evidence acceptance, approval pathways, and compliance requirements to navigate the evolving regulatory environment and accelerate product market entry strategies.
    • Competitive Positioning in US : Identify key US market players, their market share, strategic initiatives, and competitive advantages to benchmark your organization's performance and develop differentiated go-to-market strategies for the US healthcare ecosystem.
    • Pharma and Payer Adoption Trends : Analyze adoption patterns among US pharmaceutical companies, healthcare providers, and payers to identify emerging opportunities, customer pain points, and revenue models tailored to the US market's unique dynamics and requirements.
    • Technology and Data Source Analysis : Explore the US landscape of RWE data sources, analytics platforms, and emerging technologies including EHR integration, claims data, and digital health tools to identify partnership and investment opportunities aligned with market evolution.

    Frequently asked questions

    What is the current size of the US Real World Evidence Solutions Market?

    The US Real World Evidence Solutions Market is valued at $2,880.6 million in 2025, making it a significant segment within the broader healthcare technology landscape.

    What is the projected market size for the US by 2030?

    The US Real World Evidence Solutions Market is projected to reach $5,624.2 million by 2030, nearly doubling from its 2025 valuation.

    What is the growth rate of the US Real World Evidence Solutions Market?

    The US market is expected to grow at a compound annual growth rate (CAGR) of 14.3% between 2025 and 2030.

    What factors are driving growth in the US Real World Evidence Solutions Market?

    Key drivers include FDA regulatory support for real-world evidence, increasing adoption by pharmaceutical and biotech companies, growing demand for post-market surveillance, and advances in data analytics and interoperability standards.

    Who are the primary users of real-world evidence solutions in the US?

    Primary users include pharmaceutical and biotech companies, healthcare providers, payers, regulatory agencies, and contract research organizations seeking to leverage real-world data for clinical development and reimbursement decisions.

    RESEARCH METHODOLOGY

    The study involved five activities to estimate the current size of the real world evidence solutions market. Exhaustive secondary research was conducted to collect information on the market and its varied subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

    Secondary Research

    In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to to identify and collect information for the study of the real world evidence solutions market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends, to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various supply-side & demand-side sources were interviewed to obtain qualitative & quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, biostatisticians, and related key executives from various companies and organizations operating in the real world evidence solutions market. Primary sources from the demand side included industry experts, such as directors of pharmaceutical, biopharmaceuticals, medical device companies, contract manufacturing organizations, directors of RWE vendor companies, directors of clinical research organizations, and other related key executives.

    The following is a breakdown of the primary respondents:

    Real World Evidence Solutions Market

    Note 1: Others include sales, marketing, and product managers.

    Note 2: Tiers of companies are defined based on their total revenues. As of 2024. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the RWE solutions market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research.
    • In terms of value, the industry’s supply chain and market size have been determined through primary and secondary research processes.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
    Real World Evidence Solutions Market

    Data Triangulation

    The market was split into several segments and subsegments after arriving at the overall market size using the market size estimation processes. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the RWE solutions market.

    Market Definition

    Real world evidence is the clinical evidence about the usage & potential benefits or risks of a medical product derived from real world data analysis. This evidence is derived from the analysis of real world data (RWD), information collected from sources such as electronic health records, insurance claims, patient registries, and data gathered from other sources (such as digital health technologies) that can inform individuals on health status.

    Stakeholders

    • Original Equipment Manufacturers
    • Pharmaceutical & Biotechnology Companies
    • Medical Device Companies
    • Clinical Laboratories
    • Contract Research Organizations
    • Medical Device Research & Consulting Firms
    • Academic & Research Institutes
    • Government Associations
    • Market Research & Consulting Firms
    • Venture Capitalists & Investors
    • Hospitals & Clinics
    • Insurers
    • Academic Medical Centers
    • Government Research Organizations
    • Contract & Research Organizations
    • Regulatory Agencies

    Report Objectives

    • To define, describe, and forecast the global RWE solutions market based on component, application, revenue model, deployment mode, end user, and region.
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, opportunities, and challenges)
    • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and to provide details of
      the competitive landscape for market leaders.
    • To forecast the size of the market segments with respect to five regions, namely,
      North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. (along with country-wise segments)
    • To profile the key players and comprehensively analyze their market shares and core competencies in the RWE solutions market.
    • To track & analyze competitive developments such as business expansions, partnerships, agreements, collaborations, acquisitions, and innovative product/service launches in the global RWE solutions market.

    Get the Full Real World Evidence Solutions Market Report

    Full forecast, segment splits, and company analysis for all Real World Evidence Solutions Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status